# Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

> **NCT07408804** · NA · RECRUITING · sponsor: **Bangladesh Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Unresectable Hepatocellular Carcinoma (HCC)

## Interventions

- **PROCEDURE:** TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib)
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT07408804
- **Lead sponsor:** Bangladesh Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-08
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-09-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07408804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07408804, "Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07408804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*